Skip to content
CityAM
Main navigation
Sign Up
  • News
    • Latest News
    • Property
    • Media
    • Technology
    • Retail and leisure
    • Transport and infrastructure
    • Law & professional services
    • Legal Notices
    • Banking
    • Politics
    • CFA Institute Talk
  • Markets & Economics
    • Markets & Economics News
    • Economics
    • Markets
    • The Trend Micro Cybersecurity Knowledge Hub
    • Talk Crypto
    • Schroders Talk
    • M&A Talk
  • Crypto A.M.
    • Crypto News
    • Crypto Magazine
    • Crypto AM Summit & Awards 2022
  • Opinion
    • Features
    • Letters
    • The City View
  • Money
    • Jobs and Money News
    • Personal Development
    • Jobs
    • Fintech
    • Money
    • Personal Finance
    • Doceo
    • Warwick Business School
  • Unwind
    • Life & Style
    • Sport
    • The Punter
    • LIV Golf
    • Travel
    • Sport Business
    • The Punter Podcast
    • Aramco Team Series
    • Culture
    • The Magazine
    • The DiverCity Podcast
  • Impact A.M.
  • Latest Paper
  • Jobs
  • CityAM Awards 2023

Pharmaceuticals

  • Warning of Lemsip, cough and cold medicine shortage as Brits battle winter flu

    Winter woes

     Brits are struggling to get hold of cough and cold medicine as a nasty strain of flu sweeps the nation.  It has been reported that there is a shortage of medicines such as throat lozenges, cough mixtures, Lemsip powders and pain killers. This comes after the UK Health and Security Agency issued a warning about [...]

  • Eyes peeled: Five technologies to watch next year

    frontier tech

    The year of the Great Tech Sell-Off is coming to a close. But in this Digital Age, technology is only going to get more exciting, useful, and ethically questionable – so here’s five technologies to watch out for next year. SOLAR Solar power is becoming cheaper, more efficient and increasingly attractive for Brits looking to [...]

  • Drug developer files patents for cancer treatment which ‘outperforms’ AstraZeneca offering

    PHARMACEUTICALS

    Drug development company Nuformix has reformulated and improved one of AstraZeneca’s top cancer drugs, piquing investor interest today. Shares in the London-listed firm jumped nearly a quarter to 35p per share by early afternoon on Tuesday. Nuformix, which focuses on fibrosis and cancer drug repurposing, announced that the drug, known as Olaparib, had “outperformed” AstraZeneca’s [...]

  • European regulator injects hope into AstraZeneca’s bid to tackle cancer

    December 19, 2022

    The European Medicines Agency has handed AstraZeneca a number of recommendations and one approval for a trio of cancer drugs the Big Pharma firm is looking to market in the continent. AstraZeneca’s cancer drug Enhertu has been given the green light by the European regulator for use among patients with gastric cancer. Around 136,000 cases [...]

  • Drug developer C4X shares fly after signing £330m AstraZeneca licensing deal

    November 28, 2022

    Drug developer C4X Discovery has signed an exclusive licensing agreement worth up to $402m (£334m) with pharma giant AstraZeneca to develop oral therapy to treat inflammatory diseases. London-listed C4XD’s shares have rocketed this morning, up nearly 40 per cent to 28.5p so far. As part of the deal, C4XD will receive pre-clinical milestone payments worth up [...]

  • Merck inks £1.1bn deal for cancer drug developer Imago

    November 21, 2022

    American pharmaceutical giant Merck has today inked a $1.35bn (£1.14bn) deal for cancer drug developer Imago BioSciences. The offer of $36 (£30.4bn) a share represents a nearly 107 per cent premium on the company’s last closing price. The deal is intended to bolster Merck’s portfolio of blood disorder treatments, with onlookers expecting the company’s blockbuster [...]

  • Getting The Care You Need

    November 17, 2022  |  Sponsored

    Seeking help for your health concern in the right place within the NHS is critical to ensuring you receive the appropriate care at the right time. Practical support and resources are accessible via .nhs.uk to help you find the right first step towards getting the care you need. The online service offers A-Z guides on [...]

  • US pharma giants to merge under $145m deal to tackle opioid overdose epidemic

    November 14, 2022

    Indivior, a US pharmaceutical heavyweight, has bought addiction and overdose treatment competitor Opiant Pharmaceuticals for $145m (£123m) The FTSE 250 pharma firm is coughing up some $20.00 per share in cash upfront, Indivior said in a statement today. Plus, a further $8.00 a piece should revenue milestones be achieved over the next seven years. Both [...]

  • Roche shares dip as hope for long-awaited Alzheimer’s drug quickly fades

    November 14, 2022

    Shares in Swiss pharmaceutical giant dipped today after disappointing results from its late-stage Alzheimer’s drug. The drug, known as Gantenerumab, was seen as a high-risk but high-reward drug, according to Sebastian Skeet, senior healthcare analyst at investment research firm Third Bridge. However, the treatment failed to slow the progression of dementia across two ongoing trials. [...]

  • Johnson & Johnson to face UK class action lawsuit over talc asbestos claims

    November 9, 2022

    Johnson & Johnson is set to face a class-action lawsuit brought forward by high-profile Houston litigator Mark Lanier’s new UK-based firm. The Houston litigator’s new law firm is launching a British class-action lawsuit against Johnson & Johnson over claims the New Jersey pharma giant’s talc products caused UK customers to develop cancer. The lawsuit is [...]

Posts navigation

  • Page 1
  • Page 2
  • Page 3
  • …
  • Page 11
  • Next

Trending Articles

  • Severn Trent becomes first FTSE 100 firm to have female chair, CEO and CFO

  • World's richest football clubs 2023: Manchester City retain top spot as Premier League clubs dominate Deloitte Football Money League - see the full ranking

  • Reddit user's outrageous pan project sends internet into meltdown

  • Nolly review: Helena Bonham Carter reaches career high in Russell T Davies' ITV triumph

Subscribe

Subscribe to the City A.M. newsletter to have our top stories delivered directly to your inbox.

Subscribe
  • About us
  • Advertising
  • Contact
  • Terms & Conditions
  • Privacy Policy
  • News
  • Markets & Economics
  • Opinion
  • Jobs and Money
  • Unwind
  • Crypto A.M.
  • The Punter
  • COP 26
  • Awards 2023

Follow us for breaking news and latest updates

  • Newsletters
  • Latest paper
  • Advertising
  • CryptoAM.io
  • Awards
  • About
  • Tickets
Copyright 2023 City A.M. Limited